News
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Zacks Investment Research on MSN1d
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Wall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results ...
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Fintel on MSN3d
Oppenheimer Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback